TriSalus Life Sciences (NASDAQ:TLSI) Stock Rating Lowered by Wall Street Zen

TriSalus Life Sciences (NASDAQ:TLSI) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Sunday.

A number of other brokerages have also weighed in on TLSI. Weiss Ratings restated a “sell (e+)” rating on shares of TriSalus Life Sciences in a research note on Monday, December 29th. Canaccord Genuity Group increased their price objective on shares of TriSalus Life Sciences from $11.00 to $12.00 and gave the stock a “buy” rating in a report on Wednesday, December 17th. Finally, Zacks Research raised shares of TriSalus Life Sciences from a “strong sell” rating to a “hold” rating in a research note on Tuesday, December 16th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $11.00.

TriSalus Life Sciences Trading Up 1.5%

NASDAQ TLSI opened at $4.75 on Friday. The firm has a market cap of $237.31 million, a price-to-earnings ratio of -2.35 and a beta of 0.42. TriSalus Life Sciences has a 1-year low of $3.42 and a 1-year high of $7.95. The company has a 50 day moving average of $6.23 and a 200-day moving average of $5.27.

TriSalus Life Sciences (NASDAQ:TLSI) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.96) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.79). The company had revenue of $11.57 million during the quarter, compared to analysts’ expectations of $11.76 million. On average, analysts forecast that TriSalus Life Sciences will post -1.55 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Police & Firemen s Retirement System of New Jersey bought a new stake in shares of TriSalus Life Sciences during the second quarter worth approximately $29,000. JPMorgan Chase & Co. grew its holdings in TriSalus Life Sciences by 35,804.8% during the 2nd quarter. JPMorgan Chase & Co. now owns 7,540 shares of the company’s stock worth $41,000 after acquiring an additional 7,519 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in TriSalus Life Sciences during the 2nd quarter worth $47,000. HighMark Wealth Management LLC bought a new stake in shares of TriSalus Life Sciences during the 4th quarter valued at $75,000. Finally, Sequoia Financial Advisors LLC acquired a new position in shares of TriSalus Life Sciences in the 3rd quarter valued at $90,000. Institutional investors own 2.58% of the company’s stock.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.